Traumatic Brain Injuries Assessment Market Size & Share 2026-2035

Traumatic Brain Injuries Assessment Market Size

The global traumatic brain injuries (TBI) assessment market was valued at USD 2.3 billion in 2025 and is projected to reach USD 4 billion by 2035, expanding at a CAGR of 5.2% from 2026 to 2035.

Demand rests on a persistent clinical burden and on the need to determine, quickly and objectively, which patients require imaging, intensive monitoring, or follow-up care.

TBI creates demand across emergency, imaging, laboratory, and neurocritical-care pathways rather than through a single diagnostic event. The Global Burden of Disease study recorded 20.84 million incident cases and 37.93 million prevalent cases worldwide in 2021, with an age-standardized incidence of 259 per 100,000 people.^{[1]Frontiers in Public Health, Global, regional, and national burdens of traumatic brain injury from 1990 to 2021, 2025, frontiersin.org} In the U.S. 214,110 TBI-related hospitalizations were reported in 2020, while 68,663 TBI-related deaths occurred in 2023.^{[2]CDC, TBI Data | Traumatic Brain Injury & Concussion, accessed 2025, cdc.gov} Falls increasingly shape demand in aging economies, whereas road-traffic injuries remain a central cause in lower- and middle-income settings, where trauma volumes can rise faster than formal diagnostic capacity.

Assessment is moving from a CT-centered pathway toward a layered model. CT and MRI remain essential for identifying acute hemorrhage, fractures, contusions, and diffuse injury, but biomarker assays, EEG-based systems, near-infrared hematoma detection, and eye-tracking tools can provide earlier risk stratification or extend assessment beyond imaging-equipped centers. Screening devices account for USD 1,876.8 million in 2025, or approximately 80.1% of market revenue. Monitoring devices generate USD 465.1 million but grow faster, at a 6.1% CAGR, because severe TBI management increasingly depends on continuous intracranial and cerebral oxygenation data.

Hospitals remain the commercial center of gravity, representing USD 1,356.2 million in 2025, or approximately 57.9% of revenue. Their concentration of emergency departments, trauma teams, imaging suites, laboratories, and neurocritical-care beds allows them to deploy both capital equipment and recurring-use consumables. Regionally, North America contributes USD 940.2 million in 2025, while Asia Pacific, valued at USD 546.7 million, is forecast to expand at the fastest regional CAGR of 6.7%.

This transition changes the revenue mix more than it displaces imaging outright. A biomarker test that avoids an unnecessary CT in mild TBI may reduce imaging utilization for a subset of presentations, yet it also builds recurring consumable demand and can improve routing of higher-risk patients into imaging and monitoring pathways. Suppliers with installed laboratory analyzers, trauma-center relationships, service capacity, and evidence supporting workflow integration are better positioned than vendors offering a standalone technical feature. The 5.2% growth outlook reflects durable injury incidence and clinical need, tempered by workforce shortages, reimbursement uncertainty, and uneven access to high-acuity care.

The assessment covers the global traumatic brain injuries assessment market from 2026 to 2035, using 2025 as the base year. Product coverage includes screening devices, comprising CT scan, MRI, and other screening devices, and monitoring devices, comprising ICP monitoring and pBrO2 monitoring. End-use coverage includes hospitals, diagnostic centers, and other end users. Geographic coverage includes North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, with country scope covering the U.S. and Canada; Germany, UK, France, Spain, Italy, and the Netherlands; China, Japan, India, Australia, and South Korea; Brazil, Mexico, and Argentina; and South Africa, Saudi Arabia, and UAE.

Key Drivers

Growing Incidence of Traumatic Brain Injuries

The underlying injury burden produces demand that is resistant to elective-care cycles. Global incident TBI cases increased by 53.3% between 1990 and 2021, even as age-standardized incidence declined, indicating that population growth and aging are expanding the absolute clinical workload. In the U.S. adults aged 75 years and older accounted for approximately 32% of TBI-related hospitalizations, linking falls prevention, geriatric care, and emergency neuroimaging demand.

The causal mix also matters commercially. Road-traffic injuries generate high-acuity trauma demand in markets with fast motorization and uneven road-safety infrastructure, while falls produce a sustained diagnostic burden among older adults in developed health systems.^{[3]Journal of Neurosurgery, Estimating the global incidence of traumatic brain injury, 2019, thejns.org} East Asia recorded 4.31 million TBI cases in 2021, with 69.85% classified as moderate or severe, creating a clinical setting in which imaging and neurocritical monitoring have greater relevance than low-acuity concussion screening alone. Severe TBI also carries considerable hospital costs: a European study reported mean in-hospital costs of approximately €26,595, rising to €47,255 for patients receiving ICP monitoring.^{[4]Journal of Neurotrauma, Intramural Healthcare Consumption and Costs After Traumatic Brain Injury: A CENTER-TBI Study, 2023, doi.org}

Technological Advancements in TBI Assessment

Recent technology launches address different bottlenecks in the care pathway. Philips and SyntheticMR introduced Smart Quant Neuro 3D in February 2024, combining AI-based reconstruction with quantitative tissue assessment. The platform automates segmentation of white matter, grey matter, cerebrospinal fluid, and myelin from a single acquisition, with post-processing in under 10 seconds. Its value in TBI lies in more objective characterization of white-matter injury, including abnormalities that may not be apparent on conventional MRI.

Blood-based biomarker testing is creating a laboratory-based triage alternative for selected mild-TBI presentations. bioMérieux received FDA 510(k) clearance for VIDAS TBI on May 1, 2024; the assay measures GFAP and UCH-L1 and reports results in approximately 39 minutes on VIDAS 3 and VIDAS KUBE analyzers. Clinical evidence reviewed by the Association for Diagnostics & Laboratory Medicine indicates that blood-based biomarkers can support identification of patients unlikely to have CT-visible lesions, while guidelines have increasingly recognized GFAP and UCH-L1 in TBI assessment.

Innovation also extends to neurocritical monitoring. Integra re-launched CereLink in the first quarter of 2024 following its prior global removal, and reported high-single-digit growth in neuro monitoring during the fourth quarter of 2024, driven by CereLink. The market consequence is not simply more device choice: improved data presentation and workflow integration can influence whether continuous monitoring is operationally viable in already constrained intensive-care settings.

Increasing Demand for Non-Invasive Devices for TBI Assessment

Non-invasive devices expand the addressable market because they reduce dependence on surgical access, full imaging infrastructure, or specialist setup. BrainScope's Ahead 500 platform combines a Structural Injury Classifier, Brain Function Index, and Concussion Index in an FDA-cleared EEG-based system. The company reports that emergency-department deployment may reduce head CT use by more than 30%. Such systems compete on their ability to improve early decisions without requiring a laboratory turnaround or invasive procedure.

Nihon Kohden's CerebAir wireless EEG headset reduces electrode application time from more than 30 minutes to approximately five minutes, making continuous EEG more practical for ICU teams without immediate neurophysiology support. Natus Medical's BrainWatch and Moberg CNS platforms similarly seek to consolidate real-time EEG and multimodal neurological data for critical-care use. These systems address the operational friction of conventional monitoring, which often depends on scarce specialist personnel.

Field applications provide a distinct rationale for portable assessment. InfraScan's Infrascanner 2500 uses near-infrared spectroscopy to identify certain intracranial hematomas in under three minutes. In studies involving 1,293 patients, the technology showed adult sensitivity of 92.5% and specificity of 82.9% for its intended use. Oculogica's EyeBOX provides a concussion-related score in under four minutes without requiring a pre-injury baseline, positioning eye tracking for emergency, sports, and pediatric pathways where symptom-based evaluation can be inconsistent.

Rising Awareness Regarding Traumatic Brain Injury

Clinical awareness is increasingly being converted into more structured assessment pathways. A survey referenced by the Association for Diagnostics & Laboratory Medicine found strong clinician interest in blood-based testing as a more objective complement to clinical decision rules. Recommendations from clinical and trauma organizations have also begun to recognize GFAP and UCH-L1 for triage and severity assessment.

This shift matters because it affects formularies, emergency protocols, and training requirements. Demand for portable assessment is supported by concussion management in sports, field care in military settings, and a broader preference for objective measurement before return-to-activity decisions. Regulatory clearances provide an entry point, but sustained adoption depends on evidence, reimbursement, clinical workflow fit, and the availability of personnel able to interpret or act on results.

Key Restraints

Dearth of Skilled Professionals

TBI assessment requires different forms of expertise at different points in care: radiology interpretation, neurosurgical access for invasive monitoring, neurocritical-care management, and EEG review. Consequently, device availability does not automatically translate into utilization. The U.S. neurologist workforce was projected to face a shortfall of approximately 3,380 full-time equivalents by 2025, with demand of about 21,440 FTEs against supply of about 18,060.

The shortage is geographically concentrated. Non-metropolitan areas are projected to have neurologist adequacy equal to only 21.4% of demand by 2037, compared with 102% in metropolitan locations. Appointment delays compound the access problem: Medicare patients wait an average of 34 days for an initial neurology consultation, and nearly one-fifth wait longer than three months. For suppliers, this elevates the value of systems that simplify acquisition, automate preliminary analysis, or permit specialist review across a network, but it does not eliminate the need for clinically accountable interpretation.

High Cost of Assessment Devices

Cost barriers are most acute where the injury burden is high but trauma infrastructure is thin. CT and MRI require capital investment, service support, staffing, and facility readiness. ICP and pBrO2 monitoring introduce additional procedure, ICU, and consumable costs. European TBI cost data show that intracranial abnormalities on CT materially increase in-hospital costs, while ICP monitoring is associated with substantially higher spending than non-monitored care.

Hospitals therefore evaluate assessment technologies against both clinical and operating budgets. In lower-income markets, import dependence, limited service networks, and competing public-health priorities constrain adoption of premium imaging and monitoring platforms. Community hospitals in developed markets face similar economics when patient volumes cannot justify dedicated neurodiagnostic equipment. Lower-capital technologies may improve access, but their adoption remains dependent on reimbursement, staff training, data integration, and dependable supply of test consumables.

Cost pressure favors modalities that either prevent low-value escalation or extend assessment to sites without full imaging capability. Blood biomarkers may reduce avoidable CT use in selected mild-TBI presentations, while portable EEG, NIR, and eye-tracking systems can provide actionable screening information outside major trauma centers. Their commercial success will nevertheless depend on care-pathway adoption. A technically capable device without a reimbursement route, protocol placement, training model, or service infrastructure remains a limited-access product.

Traumatic Brain Injuries Assessment Market Segment Analysis

By Product

Screening Devices

Screening devices generate USD 1,876.8 million in 2025, representing approximately 80.1% of market revenue, and are forecast to grow at a 5.0% CAGR. Their scale reflects the centrality of structural assessment in acute TBI care. CT provides rapid evaluation of hemorrhage and fracture, while MRI adds soft-tissue and white-matter characterization for subacute injury, persistent symptoms, and complex neurological assessment.

CT Scan

CT Scan represents USD 950.1 million in 2025 and is projected to grow at a 4.7% CAGR. CT remains the first-line imaging modality for suspected acute TBI because speed and availability are decisive when identifying traumatic hemorrhage and determining surgical or observation needs.^{[5]Amsterdam UMC, Standardized reporting for Head CT Scans in patients suspected of traumatic brain injury (TBI), 2024, pure.amsterdamumc.nl} Technology upgrades are focused on reducing transport risk and radiation exposure rather than replacing CT. Siemens' SOMATOM On.Site mobile head CT demonstrated image quality approaching that of a conventional 64-slice stationary scanner in a prospective comparison, allowing neurocritical patients to be imaged closer to their point of care. Deep-learning denoising has also enabled diagnostic neuroradiological trauma CT at approximately 25% of standard radiation dose in published research.

FUJIFILM's SCENARIA View combines a 64-channel, 128-slice architecture with automated segmentation tools and standardized head-positioning support.^{[6]FUJIFILM Healthcare Americas, SCENARIA View CT System, accessed 2025, healthcaresolutions-us.fujifilm.com} GE HealthCare's Revolution CT platform incorporates GSI Neuro dual-energy capability that can help distinguish contrast from hemorrhage after contrast administration. These features reinforce CT's role where trauma teams need fast, repeatable scans, although mature installed bases and capital-replacement cycles limit its growth rate relative to newer monitoring categories.

Magnetic Resonance Imaging (MRI)

Magnetic Resonance Imaging (MRI) accounts for USD 853.4 million in 2025 and is estimated to grow at a 5.4% CAGR. MRI is particularly relevant when CT does not explain persistent neurological symptoms or when diffuse axonal injury, contusions, and white-matter changes require more detailed characterization. Philips' Smart Quant Neuro 3D combines SmartSpeed reconstruction with SyMRI NEURO 3D quantitative assessment, offering automated tissue segmentation and myelin-volume mapping in under 10 seconds of post-processing. The platform's ability to quantify tissue characteristics makes MRI increasingly relevant in subacute assessment and follow-up, rather than only in conventional diagnostic imaging.

Other Screening Devices

Other Screening Devices generate USD 73.4 million in 2025 and are forecast to grow at a 4.4% CAGR. This category includes the technologies most likely to change initial triage decisions. bioMérieux's VIDAS TBI provides GFAP and UCH-L1 results in approximately 39 minutes, while Abbott's assay for Alinity i and Architect i1000SR instruments reports results in 18 minutes. EEG-based BrainScope assessment offers another route to lower-radiation, point-of-care triage. These technologies are commercially differentiated by their ability to operate before, alongside, or outside conventional imaging, rather than by attempting to replace imaging for all injury types.

Monitoring Devices

Monitoring devices generate USD 465.1 million in 2025 and are projected to grow at 6.1%, the fastest rate across product categories. Their expansion reflects the need to prevent secondary injury after severe TBI, when a single baseline image cannot capture evolving intracranial pressure, oxygenation, or electrophysiological deterioration.

Intracranial Pressure (ICP) Monitoring

Intracranial Pressure (ICP) Monitoring represents USD 403.2 million in 2025 and is forecast to expand at 6.3%. ICP monitoring supports decisions around osmotherapy, sedation, cerebrospinal fluid drainage, and decompression in severe TBI. Integra's CereLink relaunch illustrates continuing investment in this established category, while its 2024 performance indicates that workflow and usability improvements can reinvigorate demand. RAUMEDIC's NEUROVENT catheters are designed for parenchymal, ventricular, and epidural use, with options to measure ICP, intracranial temperature, and ptiO2 through a single insertion. Combining parameters may reduce procedural complexity where multiparameter monitoring is clinically indicated.

Partial Pressure of Oxygen in Brain Tissue (pBrO2)

Partial Pressure of Oxygen in Brain Tissue (pBrO2) generates USD 61.8 million in 2025 and is forecast to grow at 4.6%. pBrO2 monitoring supplies localized cerebral oxygenation information that systemic oxygen saturation cannot provide. RAUMEDIC's multifunction catheter configuration supports combined ICP and oxygen monitoring, while Natus Medical's Moberg CNS Monitor integrates EEG, ICP, pBrO2, and other physiological inputs into a synchronized bedside environment. Adoption remains more selective than ICP monitoring because it requires specialized protocols, interpretation expertise, and high-acuity care settings.

By End Use

Hospitals

Hospitals account for USD 1,356.2 million in 2025, or approximately 57.9% of market revenue, and are forecast to grow at 5.6%. They are the primary buyers of CT, MRI, neurocritical monitoring systems, and laboratory biomarker analyzers because moderate and severe TBI presentations are concentrated in emergency departments and trauma centers. Their purchasing decisions extend beyond device specifications to include service contracts, clinical integration, consumables, and training.

Hospital demand is also where biomarker adoption can be most consequential. An assay integrated into an existing clinical laboratory can affect emergency-department routing without requiring a separate imaging installation. Conversely, invasive monitoring depends on neurosurgical access and ICU capacity. This combination explains why hospitals remain both the largest end-use segment and the most significant setting for suppliers seeking recurring revenue.

Diagnostic Centers

Diagnostic centers generate USD 781.7 million in 2025 and are projected to grow at 4.9%. Their role is weighted toward follow-up imaging, post-concussive evaluation, and stable patients requiring detailed MRI assessment. They supplement hospital imaging capacity in mature markets and can provide an important access route in countries where hospital-based MRI availability is uneven.

Their growth is moderated by the fact that acute, high-intensity TBI assessment remains hospital-led. Diagnostic centers benefit when patients require repeat imaging or advanced soft-tissue characterization, but they are less exposed to the procedural and monitoring intensity associated with severe trauma.

Other End Users

Other end users account for USD 204.0 million in 2025 and are estimated to grow at 4.2%. This category includes military health systems, sports medicine programs, rehabilitation centers, urgent-care facilities, and emergency medical services. Its needs are centered on portability, rapid results, and performance in settings without a full hospital diagnostic pathway.

InfraScan's deployment in U.S. Marine Corps battalion aid stations demonstrates the relevance of NIR hematoma screening in field care. ZOLL's TBI Dashboard, cleared by the FDA in July 2021, trends SpO2, systolic blood pressure, and EtCO2 to support prevention of secondary brain injury during transport. Oculogica's EyeBOX is also relevant to sports and pediatric concussion pathways because it does not require a pre-injury baseline.

The most important competitive shift within screening is functional specialization. CT remains the rapid anatomical gatekeeper, MRI broadens value in subacute and complex injury, and biomarkers or portable neurodiagnostics address uncertainty before imaging or in low-infrastructure settings. Hospitals are therefore likely to remain the decisive commercial account: they control equipment placement, care protocols, laboratory utilization, and the volume of patients that supports recurring consumable demand.

Traumatic Brain Injuries Assessment Market Regional Analysis

North America

North America generates USD 940.2 million in 2025, representing approximately 40.1% of global revenue, and is forecast to expand at a 4.3% CAGR. The U.S. contributes USD 881.6 million and is projected to grow at 4.2%, while Canada is forecast to grow at 6.4%. The region's market value reflects dense trauma infrastructure, established imaging capacity, reimbursement support, and the early availability of FDA-cleared diagnostics. Comprehensive epidemiological analysis reported North America's TBI incidence at approximately 1,299 cases per 100,000 population, although the region's revenue concentration also reflects more complete detection and reporting than many lower-resource markets.

Maturity moderates growth, but it also creates a receptive base for technology refresh and protocol integration. The U.S. workforce deficit in neurology constrains utilization outside metropolitan centers, strengthening the case for portable tools and networked interpretation models.^{[7]Neurology, Supply and demand analysis of the current and future US neurology workforce, 2013, pmc.ncbi.nlm.nih.gov[ 8]Journal of Neurology, Geographic disparities in the supply, demand, and adequacy of the United States neurologist workforce, 2025, read.qxmd.com} Canada's faster growth rate reflects a smaller base and the need to extend trauma and diagnostic access across geographically dispersed communities.

Europe

Europe generates USD 664.1 million in 2025 and is projected to grow at a 4.9% CAGR. Established national health systems support regular replacement of imaging fleets and adoption of standardized trauma protocols. The CENTER-TBI research network has created a substantial evidence base for neuroimaging, including analysis of more than 4,000 admission CT scans from European trauma centers. Such research infrastructure supports both clinical standardization and demand for advanced imaging and monitoring systems in academic centers.

The region is also a relevant early market for biomarker-based triage. VIDAS TBI had been CE-marked and deployed in selected European markets before U.S. clearance. A Spanish budget-impact analysis estimated annual savings of €696,634 for a hospital managing 3,500 mild-TBI patients after incorporating GFAP and UCH-L1 testing, equating to average savings of €199 per patient relative to CT-only protocols. The implication is that adoption is most likely where testing is embedded in a defined emergency pathway rather than purchased as a general laboratory capability.

Asia Pacific

Asia Pacific generates USD 546.7 million in 2025 and is forecast to expand at 6.7%, the fastest regional rate. Large injury volumes, investment in hospital capacity, and growing diagnostic-center networks underpin expansion. East Asia recorded the highest regional TBI case count in 2021, at 4.31 million cases, and 69.85% of cases in China were classified as moderate or severe. The combination of case volume and severity supports demand for both advanced imaging and neurocritical monitoring.

India illustrates the market's dual requirement for access and affordability. Road traffic injuries are a leading cause of TBI and disproportionately affect young males. Abbott launched its laboratory-based blood test for mild TBI in India in June 2025, with availability at Apollo Hospitals and Neuberg Supratech Laboratory. Japan, South Korea, and Australia have more mature imaging systems and aging populations, making them important markets for AI-enabled neuroimaging and assessment of fall-related injury. Commercial success across the region will depend on local distribution, service capability, and adaptation to highly variable hospital purchasing capacity.

Latin America

Latin America generates USD 109.7 million in 2025 and is projected to grow at a 6.2% CAGR. Demand is concentrated in emergency and trauma settings, where road-traffic injuries are a significant TBI mechanism and young males carry a disproportionate burden. Brazil and Mexico provide the region's largest commercial opportunities because their public and private health systems create different access channels for imaging and monitoring technologies.

Fiscal limits remain a material constraint. Public-sector capital budgets can delay adoption of premium imaging and neurocritical devices, while private hospitals and diagnostic centers have greater ability to deploy advanced technology. Suppliers that pair portable platforms with training, service coverage, and reliable consumable distribution are better suited to this operating environment than those reliant on single capital-equipment transactions.

Middle East and Africa

Middle East and Africa generates USD 81.2 million in 2025 and is forecast to grow at 5.7%. Saudi Arabia recorded an age-standardized TBI incidence of 681 per 100,000 population in 2021, among the highest national rates reported in the global analysis. Road-traffic injuries and falls are important demand drivers, while healthcare infrastructure investment supports procurement at major hospitals and specialized neuroscience facilities.

The UAE's high male-to-female TBI incidence ratio is associated with the region's expatriate workforce demographics and occupational exposure patterns. South Africa serves as a comparatively developed medical-device procurement base for sub-Saharan Africa, though access to advanced assessment remains limited across much of the continent. In this region, deployment depends as much on distributor quality, technical service, clinician training, and supply continuity as on device performance.

Europe offers the clearest health-economic case for biomarker integration, where defined hospital pathways and cost-accounting evidence can support payer and formulary decisions. Latin America and MEA present higher access friction. Suppliers in those regions need to solve for training, maintenance, and consumable availability alongside device placement. Networked and portable technologies can reduce geographic barriers, but they cannot fully compensate for shortages of specialist interpretation and critical-care capacity.

Traumatic Brain Injuries Assessment Market Share & Competitive Landscape

The market combines large imaging and monitoring suppliers with specialist companies serving discrete diagnostic gaps. Philips, GE HealthCare, Siemens Healthineers, FUJIFILM, and RAUMEDIC collectively account for approximately 45% of market share, reflecting their positions in CT, MRI, and invasive neuro-monitoring. Specialty competitors address areas where installed imaging infrastructure is less decisive, including biomarkers, EEG, NIR hematoma screening, eye tracking, and transport monitoring.

BIOMERIEUX

bioMérieux participates through VIDAS TBI, a GFAP and UCH-L1 assay cleared by the FDA in May 2024. The assay operates on VIDAS 3 and VIDAS KUBE analyzers and provides results in approximately 39 minutes.^{[9]bioMérieux, bioMérieux receives FDA 510(k) clearance of VIDAS TBI (GFAP, UCH-L1), May 28, 2024, biomerieux.com} Its competitive advantage is its alignment with hospital laboratory workflows and existing analyzer relationships.

BrainScope

BrainScope offers FDA-cleared EEG-based assessment through the Ahead 500 platform. Its Structural Injury Classifier, Brain Function Index, and Concussion Index support assessment of structural-injury risk and functional impairment at the point of care. The company is differentiated by a portable model that does not require laboratory testing or invasive access.

COMPUMEDICS

Compumedics supplies EEG and neurodiagnostic systems, including the Grael 4K EEG amplifier, Okti portable high-definition EEG amplifier, and CURRY multimodal neuroimaging software. Its portfolio supports advanced clinical neurology, ICU EEG, and research applications requiring integration of EEG, MEG, MRI, and CT information.

FUJIFILM

FUJIFILM competes through SCENARIA View CT, which combines 64-channel, 128-slice CT architecture with iterative reconstruction and APSE 3D automated segmentation tools under the REiLI AI brand. Its compact positioning and protocol support are relevant to community hospitals and emerging-market imaging procurements.

GE Healthcare

GE HealthCare provides CT, MRI, and clinical informatics systems for trauma assessment. Revolution CT with GSI Neuro dual-energy capability can distinguish contrast material from hemorrhage in relevant clinical settings. Its global service footprint and installed base support its presence at major trauma and neurology centers.

InfraScan

InfraScan develops portable NIR-based hematoma detection. Its Infrascanner 2500 is intended to identify certain traumatic supratentorial hematomas in field and bedside environments, with validation evidence supporting its use where CT access is limited. Military and resource-constrained settings are central to its positioning.

INTEGRA

Integra LifeSciences competes in invasive neuro-monitoring through CereLink and related neurosurgical systems. CereLink was re-launched in the first quarter of 2024 with enhanced accuracy, visualization, and usability, and helped drive high-single-digit neuro-monitoring growth in the fourth quarter of 2024. Its broader neurosurgical portfolio supports consolidated purchasing by high-acuity trauma centers.

Natus Medical

Natus Medical offers BrainWatch point-of-care EEG and the Moberg CNS Monitor for neurocritical care. The Moberg platform brings EEG, physiological inputs, and optional ICP data into a synchronized monitoring environment, while BrainWatch combines wireless monitoring with AI-powered seizure detection.

NIHON KOHDEN

Nihon Kohden supplies CerebAir wireless EEG and Neurofax systems. CerebAir's approximately five-minute application time can reduce the setup burden associated with continuous EEG, while Vital Signs Integration combines EEG with ICP and compatible bedside-monitor data. The portfolio is relevant where ICU staff need faster access to neurophysiological monitoring.

Oculogica

Oculogica's EyeBOX uses eye tracking to provide an objective concussion-related assessment without requiring a baseline test. Its April 2025 label expansion permits comparison with a normative population, extending potential use into recovery monitoring and return-to-activity decisions.

PHILIPS

Philips participates through AI-enabled MRI. Smart Quant Neuro 3D, developed with SyntheticMR, combines SmartSpeed reconstruction and quantitative tissue assessment to automate segmentation and myelin-volume mapping. The platform is differentiated in settings seeking more objective characterization of neurological tissue changes.

RAUMEDIC

RAUMEDIC specializes in microchip pressure catheters and multiparameter neuro-monitoring. Its NEUROVENT systems can support ICP, temperature, and ptiO2 measurement, while telemetric solutions extend ICP monitoring into selected ambulatory use cases. The company's value proposition centers on procedural efficiency and consumable catheter demand.

SIEMENS Healthineers

Siemens Healthineers provides CT, MRI, and decision-support technologies relevant to TBI. SOMATOM On.Site extends mobile head CT access into neurocritical settings, while CT Neuro Engine supports neuro-CT visualization and workflow. Deep-learning denoising and photon-counting CT initiatives strengthen its position in advanced neuroimaging.

ZOLL Medical

ZOLL Medical provides transport and pre-hospital monitoring platforms with TBI Dashboard functionality. The dashboard trends SpO2, systolic blood pressure, and EtCO2 to support prevention of hypoxia, hypotension, and hyperventilation during en-route care. Its position is concentrated in EMS, military, and transport environments.

Recent Industry Developments

• June 2025: Abbott launched a laboratory-based blood test for mild traumatic brain injury in India on Alinity i and Architect i1000SR instruments at Apollo Hospitals and Neuberg Supratech Laboratory. The test measures UCH-L1 and GFAP and delivers results in 18 minutes.

• April 2025: Oculogica received an expanded FDA label for EyeBOX, enabling comparison of individual eye-movement results with a normative reference population and extending use into recovery monitoring and return-to-activity assessment.

• May 2024: bioMérieux received FDA 510(k) clearance for VIDAS TBI (GFAP, UCH-L1), a serum-based automated immunoassay for mild TBI assessment on VIDAS 3 and VIDAS KUBE analyzers.

• February 2024: Philips and SyntheticMR launched Smart Quant Neuro 3D at ECR2024, combining SmartSpeed reconstruction and SyMRI NEURO 3D quantitative tissue assessment for automated brain segmentation and myelin-volume mapping.

• Q1 2024: Integra LifeSciences re-launched CereLink ICP monitoring following its 2022 voluntary global product removal, with the product contributing to high-single-digit neuro-monitoring growth in the fourth quarter of 2024.